The Board of Directors of Vystar Corporation (OTCPK:VYST) has approved preliminary plans to spin off the RxAir UV light air purification business as a separate publicly traded company. Vystar is planning the spin-off to result in Vystar shareholders owning stock in both companies in an anticipated tax-free transaction. Vystar's current plans for the spinoff include the following, some of which is subject to SEC and FINRA approval and other factors: Approximately 36 million shares authorized for RxAir NewCo. RxAir NewCo is expected to trade on the OTCQB. The Vystar Board has approved a $1,000,000, two-tranche capital raise for RxAir NewCo in advance of the spin-off. The raise will not affect Vystar or its shares. The RxAir NewCo opening day price is expected to be $2.00 per share based on the second tranche of the capital raise for RxAir at $2.00 per share. Current Vystar shareholders' ownership of shares in Vystar will remain unchanged. Vystar will retain 20% of the shares of RxAir NewCo anticipated valuation of approximately $14.5 million based on the expected opening price and number of authorized shares. Vystar will transfer to RxAir NewCo the RxAir-related patents, tooling, inventory and other assets having a value of $6-$8 million.